title: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
abstract: The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classification. Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive', and 'Triple negative (ductal)' disease, with the addition of trastuzumab in 'HER2 positive' disease. Progress was also noted in defining better tolerated local therapies in selected cases without loss of efficacy, such as accelerated radiation therapy and the omission of axillary dissection under defined circumstances. Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.
authors.affiliation: International Breast Cancer Study Group, Department of Medicine, European Institute of Oncology, Milan, Italy. aron.goldhirsch@ibcsg.org
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
authors.forename: W C
authors.initials: WC
authors.lastname: Wood
authors.forename: A S
authors.initials: AS
authors.lastname: Coates
authors.forename: R D
authors.initials: RD
authors.lastname: Gelber
authors.forename: B
authors.initials: B
authors.lastname: Thürlimann
authors.forename: H-J
authors.initials: HJ
authors.lastname: Senn
mesh_terms: D005260:Female; D006801:Humans; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000145:classification / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D035683:MicroRNAs / Q000627:therapeutic use; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D000068878:Trastuzumab; D003245:Consensus Statements as Topic
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D035683:MicroRNAs; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab